Canaccord analyst Caitlin Cronin raised the firm’s price target on Smith & Nephew to $36 from $28 and keeps a Hold rating on the shares. The firm updated its model following Q2 results noting FY25 guidance was unchanged, including continued expectations for 5% underlying growth and proforma trading margins in the range of 19-20%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNN:
- Smith & Nephew Announces Partial Vesting of 2023 Share Awards
- Smith & Nephew: Strong EU MedTech Position and Strategic Initiatives Justify Buy Rating
- Smith & Nephew price target raised to 1,300 GBp from 1,100 GBp at Berenberg
- BlackRock Adjusts Holdings in Smith & Nephew
- Smith & Nephew’s Voting Rights Shift Following BlackRock’s Acquisition